{"id":23048,"date":"2026-02-09T04:30:00","date_gmt":"2026-02-09T09:30:00","guid":{"rendered":"https:\/\/dbv-technologies.com\/press_releases\/dbv-technologies-participea-la-conference-emerging-outlook-biotech-summit-organisee-par-guggenheim-securities\/"},"modified":"2026-02-09T04:30:00","modified_gmt":"2026-02-09T09:30:00","slug":"dbv-technologies-participea-la-conference-emerging-outlook-biotech-summit-organisee-par-guggenheim-securities","status":"publish","type":"press_releases","link":"https:\/\/dbv-technologies.com\/fr\/press_releases\/dbv-technologies-participea-la-conference-emerging-outlook-biotech-summit-organisee-par-guggenheim-securities\/","title":{"rendered":"DBV Technologies participe\u00e0 la conf\u00e9rence Emerging Outlook: Biotech Summit organis\u00e9e par Guggenheim Securities"},"content":{"rendered":"<div class=\"pr-date-globe\">February 09, 2026 16:30 ET<\/div>\n<p align=\"right\">Ch\u00e2tillon, France, le 9 f\u00e9vrier &lpar;22&nbsp;:30 CET) 2026<\/p>\n<p align=\"left\"><b>DBV Technologies participe\u00e0 la conf\u00e9rence Emerging Outlook: Biotech Summit organis\u00e9e par Guggenheim Securities<\/b><\/p>\n<p align=\"justify\">DBV Technologies &lpar;Euronext : DBV \u2013 ISIN : FR0010417345 \u2013 Nasdaq Stock Market : DBVT \u2013 CUSIP : 23306J309) &lpar;la \u00ab Soci\u00e9t\u00e9 \u00bb), soci\u00e9t\u00e9 biopharmaceutique de stade avanc\u00e9, annonce aujourd\u2019hui la participation de Daniel Tass\u00e9, Directeur G\u00e9n\u00e9ral, \u00e0 une discussion informelle &lpar;\u00ab fireside chat \u00bb) dans le cadre du Guggenheim Securities Emerging Outlook: Biotech Summit, qui se tiendra les 11 et 12 f\u00e9vrier 2026 \u00e0 New York &lpar;\u00c9tats-Unis). L\u2019intervention de M. Tass\u00e9 est pr\u00e9vue le jeudi 12 f\u00e9vrier \u00e0 14h30 &lpar;heure de l\u2019Est).<\/p>\n<p align=\"justify\">Une webdiffusion en direct du \u00ab&nbsp;fireside chat&nbsp;\u00bb est accessible&nbsp;<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-pNNcko7eYUQ-hywjwOKbTaV8ZWQfi6dvsjbgHe1M4biHBkcaTI9U3eb_Q_xzaADNxwaL8JpqxVNcKlPfVxhYCzXuoeza-5Cl_UuUW_DNlfryFjZrWxyU3aSx9r1MytWOjTEqAsdPIRCHyGhUVP1iiCZBXPCcCcZdfnlPhlcKSAAD9ZX5MNcA5J4I5pqBHlKQvB3WB5iCTY7kX_UYOBch2MgwHCq5z4rKncKNS4nECGQzlT37Xl6LfSLtUQCWvlmQoVJtyjs61IZNhSA0Z3FTJrL83GOopRZ8A8V0tPFI_DLFWNeKNLQLjwC0PkKHAbtKNrXduxFvYlb_hqJyApKpwRNSzaInOuyVyWv8PIAokxCCpmKliDrDtSzNG5Xvyz5s8vPdWil6lJR63mEkUNj8DQi4ySTbg1iIl58kaKun1cw8YRQWjAhRUyKXaaBlO_BLaKoJ0dPmOgqdPcwtuI5lEI5ccNLcRxI6gWqoQ1RP3_KAltuRPiwgrc-ysC8UnxWwzH7bg59rieAaf-T88l5K4GRgSo7_XNVdCt7D6hoguJmah3GmyIkZHWGivyIp0-3gijhVzFEMqfRg17mu6mBO-GakpbAtgbPbzf7AM5LY76mt0LhzBKUqEq2Vu4rMq-iMbKHrwew5nB10qNnnPkYlQ==\" rel=\"nofollow\" target=\"_blank\" title=\"ici\">ici<\/a>&nbsp;et \u00e9galement disponible depuis le site web de la soci\u00e9t\u00e9, page Investisseurs, section \u00ab&nbsp;\u00c9v\u00e9nements \u00bb:&nbsp;<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EqSiAKRxT0ms8zqPQ2P0WcK6I1O0mkGBK6D7pXFT3yyw2T1CQYNUnowLSBsD3B28w0eCyoNFJDHpw2vtMdnpS4mataQEJJEGF_hsPP66vqGVVlVP38kQxDoYNxDH06Iaha_0iWuKM9wM-I1NLAu4-iDiqEYKrFMELS26CuEH_-UnMDFOynUurbQb8zVNzDnbrJZbvNY4P89R_u40h37oGA==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/dbv-technologies.com\/fr\/investor overview\/evenements\/<\/a>. <\/p>\n<p align=\"justify\">Un enregistrement sera accessible pendant 90 jours apr\u00e8s l\u2019\u00e9v\u00e9nement.<\/p>\n<p align=\"justify\"><b>\u00c0 propos de DBV Technologies<\/b><br \/>DBV Technologies est une entreprise biopharmaceutique de stade avanc\u00e9 sp\u00e9cialis\u00e9e dans le d\u00e9veloppement d\u2019options de traitement des allergies alimentaires et autres affections immunologiques ayant d\u2019importants besoins m\u00e9dicaux non satisfaits. DBV Technologies se concentre actuellement sur l\u2019\u00e9tude de l\u2019utilisation de sa technologie exclusive, le patch VIASKIN<sup>\u00ae<\/sup>, pour traiter les allergies alimentaires caus\u00e9es par une r\u00e9action immunitaire hypersensible et caract\u00e9ris\u00e9es par une gamme de sympt\u00f4mes dont la gravit\u00e9 varie de l\u00e9g\u00e8re \u00e0 l\u2019anaphylaxie potentiellement mortelle. Des millions de personnes vivent avec des allergies alimentaires, y compris de jeunes enfants. Gr\u00e2ce \u00e0 l\u2019immunoth\u00e9rapie \u00e9picutan\u00e9e &lpar;EPIT), le patch VIASKIN<sup>\u00ae<\/sup>&nbsp;est con\u00e7u pour dispenser des quantit\u00e9s de microgrammes d\u2019un compos\u00e9 biologiquement actif dans le syst\u00e8me immunitaire \u00e0 travers une peau intacte. L\u2019EPIT est une nouvelle classe de traitement non invasif cherchant \u00e0 modifier l\u2019allergie sous-jacente d\u2019un individu en r\u00e9\u00e9duquant le syst\u00e8me immunitaire \u00e0 se d\u00e9sensibiliser \u00e0 l\u2019allerg\u00e8ne en tirant parti des propri\u00e9t\u00e9s de tol\u00e9rance immunitaire de la peau. DBV Technologies s\u2019est engag\u00e9e \u00e0 transformer le traitement des personnes souffrant d\u2019allergies alimentaires. Les programmes d\u2019allergie alimentaire de la Soci\u00e9t\u00e9 comprennent des \u00e9tudes cliniques en cours avec le patch VIASKIN<sup>\u00ae<\/sup>&nbsp;peanut chez les jeunes enfants &lpar;de 1 \u00e0 3 ans) et les enfants &lpar;de 4 \u00e0 7 ans) allergiques \u00e0 l\u2019arachide.<\/p>\n<p align=\"justify\">Le si\u00e8ge mondial de DBV Technologies est situ\u00e9 \u00e0 Ch\u00e2tillon, en France Les op\u00e9rations nord-am\u00e9ricaines sont bas\u00e9es \u00e0 Warren, dans le New Jersey. Les actions ordinaires de la Soci\u00e9t\u00e9 sont n\u00e9goci\u00e9es sur le segment B d\u2019Euronext Paris &lpar;symbole : DBV, code ISIN : FR0010417345) et les ADS de la Soci\u00e9t\u00e9 &lpar;repr\u00e9sentant chacun cinq actions ordinaires) sont n\u00e9goci\u00e9s sur le Nasdaq Capital Market &lpar;DBVT \u2013 CUSIP : 23306J309).<\/p>\n<p align=\"justify\">Pour plus d\u2019informations, veuillez consulter&nbsp;<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=E5n1LgybWYfPUlB7BIxOdVFbpWsHTNHGW1TAgvVGrNUp-x56Qp3JUbmBBXlBCbF9FaCa0hlbHyZjFqSQxAMOVjj4rFHKhNNQ2BOQ95r9DSZVcY-xJuXYjJCG2AfhELzvpKqFGW3Mf9R2oF_ILkWn88W9bov_-V_yT8PHGG5DJoy4TQaSTz0qtjStGAsacNQR-WxG17vVIoqqYPKDq8JpJP64S3RMJiWfiladkcS2r_xqfXlJJjngw9-r1dgdR_uaO0LuEUa74oneLCT9LD4pJRA3H9N2HzdfhMNRzhrncPr941KwPp8bldmE9hKVaSp0tAF80tcm4Lb7gK0umkLUyTbNmCW0ncwuDvsgFn22lz7F1zjmI3YI_fKBdUxNmpvfK6nOmkDjWBJC00mQxqMmoNHZYotgwS3nprXdHfkx4s98kJEb2BZrof6npfdkMgB-L4zca3vQS1XMZDorJn1lupE8oQkfAb4OCIRa3hZv1opA3zd9S0ZtEsfBqlZFuReOk5fcOUQgjsBJXinA3djr3ojh949XECVODttA6f78lOQZrX-Slw9SqwNgv3D8X_GwIdZL2sG4aQQ_H0loEz3bFES_X7sNNqDEME3XjP0PHPY=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>www.dbv-technologies.com<\/u><\/a>&nbsp;et nous contacter sur&nbsp;<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=j-f-NlxjsBDC_0V5dF5GcvMPcIzwfJUYvTIqngmUVVqlLZzrdYbc_vfi1HzBXFgVvNxRfeqe21TXiVqPJt9W-Xx5H5IBagfH01IcQuCcwh-oLmZ6ZroLu2QtbUdysEwCwnMWjP9TxPukzT6DKMpWAtTiguaZQX9cSmaQXgQSuqC9fVPvX_Z15Qk9Iwj9VNogwgw3IV0917f80FgqATQxGSTwrGrs4hka3iFGiZD0MsE1K9OCJBxYVBgIHkLiNBj9GqvpYrNmvJA4HMOyFHVNNOIsN6OzLEUDmFjvz5wEVCpSczz6N7_WfXsWgWgh_-6mTnYe2jS54hbdrOgiTr3jr7PijXNudh3dsq-YA1jhdbEvqm-QuM6QrVOgtxKsBdN8nmzZrDEMQowafcoJHFI7fSPS-RLfC2FI7-bFGE9m85UWaIxcHdFBy_c8ZEzVlSCAFrfWsbXlZUTRcbbnDmq4OoDV5aUbvRXABLzv6N2Zl47LJQ7DgSMGQQvdCnIquQaZMynkhgErqwhcyvi7FityIwmWsIXj1xYp1NVyJigRvy0CyROtXdbyIlwMi4onsTzsHZ_9IaSH61ltPHuINwt-UTvQI3pdFXUviFz1J3Ykvy0=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>X &lpar;anciennement Twitter)<\/u><\/a>&nbsp;et&nbsp;<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5k30h1XpAUa-JpIRQQdwpolRx1XdS94zsaVKMQcpizI_8nyo9u6OTZ1zFN-eOBjkkaQsgFuDFIuXkG-mGu88CLWx5KbdU-KGJvkbhaOjN3MA9qeI9pn5h5qzHfATLEZH3uxniRGdOMRExqVInLOA4rCTGKqgSIqzDUISgEItggyJRnbhMoDhsFhAhn5EKsosnAewk12c8nTYrqoXtX42g9K5UEv1RpS3ZEjoJROZeSY6P0QQWxBFxzvBNqpdXGKFXI6PdIKuHSvOWPvmDzNUonvAS08zRftFoFpOtRFd96b6MFOvkO7Ln7Epykaq8sv2tNl7ECo3tE33u0wCrF_Ln42iSM-65z5mrBO1xPloTKydPt5aQsQp1J9jkzwXz4fs1raMc4xhOShD9xTyR3GiSggCS3Ootn0OKmXL5WgKcIBTtQPVRNLSkwcsvzw_PWbmh7lzHfeadUfBvmWjZqxeUg6CsiKmJojgmAIIGWovplUGwqr9LzC0ijeP8n5XDZwqOCVPNQvJKSU5DZqoo-VBJ_Mt1OzeDnerZitESxl5WFheOaFbxLh1OslzBXeeEVmQW1fI06z4k5cBZzk6VCJmcA==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>LinkedIn.<\/u><\/a> <\/p>\n<p align=\"left\"><b>Contact avec les investisseurs<\/b><br \/>Jonathan Neely<br \/>DBV Technologies<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Dvn1XSLY-13T2HtQoRwzPWPd6dQozf9NCnJLfoOGfwxAPHUPQcOQ-19zeOuYihcYYXGVRyVHMP6JO9HQ8LV1Qii61MJ0rBMIYgz5W5JiDw9nVYytFT77Rt4m1Xm67X1mByH95EGIol4pbMk5sdkNhw==\" rel=\"nofollow\" target=\"_blank\" title=\"jonathan.neely@dbv-technologies.com\">jonathan.neely@dbv-technologies.com<\/a> <\/p>\n<p align=\"left\"><b>Contact avec les m\u00e9dias<\/b><br \/>Brett Whelan<br \/>DBV Technologies<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kNwDfkyD9Hm_bmKtSbOIGvW8pdchfKDhhTBfRBzC6ryn50IA0TlRNysvSU6BY7EO6nYZFqyxEXA2gbST7Eq9GdxsGgBe03gv8JIu2RCAz9MINDc6IvqEOXnXlIJ8DO_Rbeim5sa8KVucW6rFEGKlvw==\" rel=\"nofollow\" target=\"_blank\" title=\"brett.whelan@dbv-technologies.com\">brett.whelan@dbv-technologies.com<\/a><\/p>\n<p id=\"gnw_attachments_section-header\">    <strong>Pi\u00e8ce jointe<\/strong><\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>        <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=5p_Ak8oFecntzBwzNFOygDrh68Nb9IQh24h0A8rc5CLXSFO4fBTujAp9QkJ4eCge-BknDgTnfSib9bd_EUx9uzodcWn0HSDMzEiWsNMfZsZEurb8wwmtqrfke5Wy35TzF1FIDNKgYLdqf-V4WTwS8151s-x869Bzmb9WdzcFHU0=\" title=\"version PDF\" rel=\"nofollow\">version PDF<\/a>      <\/li>\n<\/ul>\n<p><img decoding=\"async\" alt=\"\" data-src=\"https:\/\/ml-eu.globenewswire.com\/media\/Njc3ZmI5OWItOGFiOS00YWMwLWI4NDctMTI3N2UzZjljZWUzLTEwMTExNTItMjAyNi0wMi0wOS1mcg==\/tiny\/DBV-Technologies-S-A-.png\" referrerpolicy=\"no-referrer-when-downgrade\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\">            <\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"wds_primary_press_release_type":0,"footnotes":""},"press_release_type":[],"class_list":["post-23048","press_releases","type-press_releases","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases\/23048","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases"}],"about":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/types\/press_releases"}],"version-history":[{"count":0,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases\/23048\/revisions"}],"wp:attachment":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/media?parent=23048"}],"wp:term":[{"taxonomy":"press_release_type","embeddable":true,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_release_type?post=23048"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}